Clinical Research Partners, LLC

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)2 trials
• Coeliac disease2 trials
• Obesity2 trials
• Asthma1 trial
• Crohn's disease1 trial
• Gout1 trial
• Irritable bowel syndrome1 trial
• Lyme disease1 trial
• Peripheral artery disease1 trial
• Type 2 diabetes1 trial
• Ulcerative colitis1 trial
• Vitiligo1 trial

Phase

• Phase 27 trials
• Phase 36 trials
• Phase 41 trial

Status

• Recruiting6 trials
• Completed5 trials
• Active, not recruiting2 trials
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company6 trials
• Incyte Corporation2 trials
• Pfizer2 trials
• Ardelyx1 trial
• Chugai Pharmaceutical1 trial
• and 2 more

Running trials

• Recruiting

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

  NCT07533019· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Study of DONQ52 in Active Celiac Disease

  NCT07239336· Phase 2· Chugai Pharmaceutical· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Eli Lilly and Company· Source

  Contact: Kara Foster-Weiss (principal investigator)

• Recruiting

  Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

  NCT07223593· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

  NCT07215559· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

  NCT06977581· Phase 2· Pfizer· Source

• Active, not recruiting

  A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

  NCT04232553· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma1 recruiting
• Coeliac disease1 recruiting
• Obesity1 recruiting
• Peripheral artery disease1 recruiting
• Ulcerative colitis1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

  NCT06553547· Phase 2· Ardelyx· Source

• Terminated

  The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

  NCT05696392· Phase 4· Incyte Corporation· Source

• Completed

  Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

  NCT05634811· Phase 3· Pfizer· Source

• Completed

  Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

  NCT05586958· Phase 3· LG Chem· Source

• Completed

  A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

  NCT05353985· Phase 2· Takeda· Source

• Completed

  A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

  NCT04921969· Phase 3· Incyte Corporation· Source